{"id":"rvl-1201","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Mydriasis-related visual effects"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL585256","moleculeType":"Small molecule","molecularWeight":"277.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RVL-1201 works as a selective alpha-1A adrenergic receptor agonist, causing contraction of the dilator pupillae muscle in the iris to produce mydriasis. This mechanism is used to improve pupil function and visual performance in patients with presbyopia or reduced pupil size. The drug is administered as an ophthalmic solution applied directly to the eye.","oneSentence":"RVL-1201 is an alpha-1A adrenergic agonist that increases pupil dilation (mydriasis) by stimulating alpha-1A receptors on the dilator pupillae muscle.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:37.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Presbyopia (age-related loss of accommodation)"},{"name":"Reduced pupil size associated with presbyopia"}]},"trialDetails":[{"nctId":"NCT01848041","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis","status":"COMPLETED","sponsor":"RVL Pharmaceuticals, Inc.","startDate":"2013-05","conditions":"Blepharoptosis","enrollment":46},{"nctId":"NCT02436759","phase":"PHASE3","title":"Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis","status":"COMPLETED","sponsor":"RVL Pharmaceuticals, Inc.","startDate":"2015-05","conditions":"Acquired Blepharoptosis","enrollment":140},{"nctId":"NCT03536949","phase":"PHASE3","title":"Study of Safety of RVL-1201 in Treatment of Blepharoptosis","status":"COMPLETED","sponsor":"RVL Pharmaceuticals, Inc.","startDate":"2018-06-20","conditions":"Blepharoptosis","enrollment":234},{"nctId":"NCT03565887","phase":"PHASE3","title":"Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis","status":"COMPLETED","sponsor":"RVL Pharmaceuticals, Inc.","startDate":"2018-06-28","conditions":"Blepharoptosis","enrollment":164}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxymetazoline Hydrochloride Ophthalmic Solution 0.1%"],"phase":"phase_3","status":"active","brandName":"RVL-1201","genericName":"RVL-1201","companyName":"RVL Pharmaceuticals, Inc.","companyId":"rvl-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RVL-1201 is an alpha-1A adrenergic agonist that increases pupil dilation (mydriasis) by stimulating alpha-1A receptors on the dilator pupillae muscle. Used for Presbyopia (age-related loss of accommodation), Reduced pupil size associated with presbyopia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}